| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 27, 2006
From the Departments of Neurology (H.M.S., K.C.A., N.R.G., A.M.K., R.M.S., J.C.G., E.A.N.) and Radiology (R.U.W., E.D.C.), University of Texas-Houston Medical School, Houston, Tex, and the Department of Neurology (M.S.C., III), Alabama Neurological Institute, Birmingham, Ala. * To whom correspondence should be addressed. E-mail: James.C.Grotta{at}uth.tmc.edu.
Background and Purpose--The optimal approach for acute ischemic stroke patients who do not respond to intravenous recombinant tissue plasminogen activator (IV rt-PA) is uncertain. This study evaluated the safety and response to intra-arterial thrombolytics (IATs) in patients unresponsive to full-dose IV rt-PA. Methods--A case series from a prospectively collected database on consecutive acute ischemic stroke patients treated with IATs after 0.9 mg/kg IV rt-PA during a 7-year interval was collected. Primary outcome measures included symptomatic intracranial hemorrhage and mortality. As indicators of response, secondary outcome measures were recanalization and discharge disposition. Results--Sixty-nine patients (mean±SD age, 60±13 years; range, 26 to 85 years; 55% male) with a median pretreatment National Institutes of Health Stroke Scale score of 18 (range, 6 to 39) were included. IV rt-PA was started at 124±32 minutes (median, 120 minutes) and IAT, at 288±57 minutes (median, 285 minutes). IATs consisted of reteplase (n=56), alteplase (n=7), and urokinase (n=6), with an average total dosage of 2.8 U, 8.6 mg, and 700 000 U, respectively. Symptomatic intracranial hemorrhage occurred in 4 of 69 (5.8%) patients; 3 cases were fatal. Recanalization was achieved in 50 (72.5%) and a favorable outcome (home or inpatient rehabilitation) in 38 (55%). Conclusions--IAT therapy after full-dose IV rt-PA in patients with persisting occlusion and/or lack of clinical improvement appears safe compared with IV rt-PA alone or low-dose IV rt-PA followed by IAT. A high rate of recanalization and favorable outcome can be achieved.
Revised on August 7, 2006
Accepted on August 22, 2006
Is Intra-Arterial Thrombolysis Safe After Full-Dose Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke?
Hashem M. Shaltoni MD;
This article has been cited by other articles:
![]() |
R.G. Nogueira, A.J. Yoo, F.S. Buonanno, and J.A. Hirsch Endovascular Approaches to Acute Stroke, Part 2: A Comprehensive Review of Studies and Trials AJNR Am. J. Neuroradiol., May 1, 2009; 30(5): 859 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hallevi, A. D. Barreto, D. S. Liebeskind, M. M. Morales, S. B. Martin-Schild, A. T. Abraham, J. Gadia, J. L. Saver, the UCLA Intra-Arterial Therapy Investigators, J. C. Grotta, et al. Identifying Patients at High Risk for Poor Outcome After Intra-Arterial Therapy for Acute Ischemic Stroke Stroke, May 1, 2009; 40(5): 1780 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.C. Burns, G.J. Rodriguez, S. Patel, H.M. Hussein, A.L. Georgiadis, K. Lakshminarayan, and A.I. Qureshi Endovascular Interventions following Intravenous Thrombolysis May Improve Survival and Recovery in Patients with Acute Ischemic Stroke: A Case-Control Study AJNR Am. J. Neuroradiol., November 1, 2008; 29(10): 1918 - 1924. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. De Keyser, Z. Gdovinova, M. Uyttenboogaart, P. C. Vroomen, and G. J. Luijckx Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations Stroke, September 1, 2007; 38(9): 2612 - 2618. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Mattle Intravenous or Intra-Arterial Thrombolysis?: It's Time to Find the Right Approach for the Right Patient Stroke, July 1, 2007; 38(7): 2038 - 2040. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |